Phase 1 Study (DRAGON) of SRK-181 (linavonkibart), a Latent TGFβ1 Inhibitor, Combined with Pembrolizumab in Patients with Anti-Pd1 Resistant Advanced Solid Tumors: Updated Results of Expansion Part.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined